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Abstract
Background: The increasing number of available genotypes for genetic studies in humans requires
more advanced techniques of analysis. We previously reported significant univariate associations
between gene polymorphisms and antidepressant response in mood disorders. However the
combined analysis of multiple gene polymorphisms and clinical variables requires the use of non
linear methods.
Methods: In the present study we tested a neural network strategy for a combined analysis of two
gene polymorphisms. A Multi Layer Perceptron model showed the best performance and was
therefore selected over the other networks. One hundred and twenty one depressed inpatients
treated with fluvoxamine in the context of previously reported pharmacogenetic studies were
included. The polymorphism in the transcriptional control region upstream of the 5HTT coding
sequence (SERTPR) and in the Tryptophan Hydroxylase (TPH) gene were analysed simultaneously.
Results: A multi layer perceptron network composed by 1 hidden layer with 7 nodes was chosen.
77.5 % of responders and 51.2% of non responders were correctly classified (ROC area = 0.731 –
empirical p value = 0.0082). Finally, we performed a comparison with traditional techniques. A
discriminant function analysis correctly classified 34.1 % of responders and 68.1 % of non
responders (F = 8.16 p = 0.0005).
Conclusions: Overall, our findings suggest that neural networks may be a valid technique for the
analysis of gene polymorphisms in pharmacogenetic studies. The complex interactions modelled
through NN may be eventually applied at the clinical level for the individualized therapy.
Background
The increasing number of available genotypes for genetic
studies in humans requires more advanced techniques of
analysis [1]. Moreover, genes interact in a complex way,
with some gene variants acting additively with others, in a
multiplicative way or with a compensatory effect [2,3].
Traditional statistical techniques are not appropriate for
detecting such effects [4], because they rely on the basic
assumption of linear combinations only [5]. Investigation
in multifactorial disorders in fact evidenced that non lin-
ear interactions are not detected by traditional regression
analyses [6].
In particular, psychiatric disorders are characterized by a
non mendelian, multifactorial genetic contribution with a
number of susceptibility genes interacting with each other
[7,8]. In the process of disentangling the contribution of
environment versus genes, it has been recently suggested
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to focus on endophenotypes instead of psychiatric syn-
dromes as a whole [9,10]. One interesting endopheno-
type is drug response, a field that gained much attention
due to the possible clinical applications, ranging from
individualized therapy to new drug development [11-14].
However, notwithstanding the promising results observed
in the pharmacogenetic field, no single major effect gene
was identified, but a variable number of polymorphisms
in various genes are supposedly involved in modulating
the response and/or side effects to drugs [15-20].
Since our initial study [21] we investigated the short term
response to Selective Serotonin Reuptake Inhibitors
(SSRIs) and a number of candidate genes, observing both
positive and negative associations [22].
However, both the increasing number of genes associated
with response and the limitations of traditional methods
of analysis are factors requiring the use of new techniques
of analysis that more closely resemble to the underlying
biological process, i.e. that allows for non-linear
interactions.
Neural networks (NN) have been proposed for such stud-
ies [1,23,24]. The main advantage of neural networks is
that complex non-linear relationships can be modelled,
potentially incorporating high-order interactions between
predictive variables. This is of particular importance in a
complex phenotype such as antidepressant response
[22,25].
NN have been used in other fields of medicine, for exam-
ple to predict cyclosporine dosage in patients after kidney
transplantation [26], perspective outcome in AIDS
research [27] but also in a genetic analysis in heart disease
analysing 10 candidate genes simultaneously [28]. More
complex models including gene-environment interac-
tions have been developed [29].
In fact, neural networks proved to outperform single
marker association tests, particularly in the case of a com-
plex mode of inheritance or where multiple mutations
result in more than one haplotype associated with the dis-
ease [25,30,31].
In the present paper we have re-analysed our sample
where polymorphism in the transcriptional control region
upstream of the 5HTT coding sequence (SERTPR) and in
the Tryptophan Hydroxylase (TPH) gene were analized
[32], in that paper we observed an association of both pol-
ymorphisms with drug response but we could not evalu-
ate their possible non linear interactions. In the present
paper we had the aim of evaluating the validity of NN
models and of comparing them with traditional statistical
techniques (multiple regression and discriminant func-
tion analysis).
Methods
Sample
The sample was already described in the original paper
[32]. Briefly, two hundred and seventeen depressed inpa-
tients were included in this study (age = 52.11 ± 12.04;
onset = 37.97 ± 12.16; female/male: 144/73; bipolars:
delusional/non delusional = 40/33, major depressives:
delusional/non delusional = 71/73). All patients were
evaluated at baseline and weekly thereafter until the sixth
week using the 21-item Hamilton Rating Scale for Depres-
sion (HAM-D-21) [33] administered by trained senior
psychiatrists blind to genetic data and to treatment (flu-
voxamine 300 mg daily from day 8 plus pindolol 7.5 mg
to one third of the sample). A decrease in HAM-D scores
to 8 or less was considered the response criterion. After the
procedure had been fully explained to all subjects,
informed consent was obtained.
Plasma fluvoxamine levels were determined by high-per-
formance liquid chromatography after 2 weeks of stable
300 mg daily dose [34]. Nine patients with extreme
plasma levels (more than 2 standard deviations) were
removed from the study in order to avoid biases due to
side effects that are present at high doses, also subjects
with plasma levels below 20 ng/ml were excluded as this
may indicate non compliance, but no cases with such low
doses were observed. The influence of both SERTPR and
TPH polymorphisms was limited to subjects not taking
pindolol [32] therefore we included in the present study
the 121 subjects including fluvoxamine alone (81
responders/40 non responders). DNA analysis was per-
formed as described in the original paper [32].
Review of the models used
Multilayer Perceptrons
This is one of the most popular network architecture in
use today, though relatively recent [35]. In MLP the units
each perform a biased weighted sum of their inputs and
pass this activation level through a transfer function to
produce their output, and the units are arranged in a lay-
ered feedforward topology. The first step of the analysis is
the choice of the number of layers and nodes. This is per-
formed searching for a minimum in the error/perform-
ance hyperplane. Once the number of layers, and number
of units in each layer, have been selected, the weight and
threshold of the network must be set so as to minimize
the prediction error made by the network. This is the role
of the training algorithms. The best-known example of a
neural network training algorithm is back propagation. In
back propagation, the gradient vector of the error surface
is calculated and used to decrease the error. A sequence of
such moves (slowing as we near the bottom – epochs) willBMC Medical Genetics 2004, 5:27 http://www.biomedcentral.com/1471-2350/5/27
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eventually find a minimum. A large number of epochs
with no further improvement in the performance suggests
that the optimum set of weights has been reached.
Linear Networks
Originally developed about 60 years ago by Fisher [36], in
classification, the hyperplane is positioned to divide the
two classes (a linear discriminant function) while in
regression, it is positioned to pass through the data. A lin-
ear model is typically represented using an NxN matrix
and an Nx1 bias vector. The linear network provides a
good benchmark against which to compare the perform-
ance of your neural networks.
Radial Basis Function Networks
In a radial basis function network the response surface of
a single radial unit is a Gaussian (bell-shaped) function,
peaked at the center, and descending outwards. RBF net-
works have advantages and disadvantages over MLPs.
First, they can model any non-linear function using a sin-
gle hidden layer, which removes some design-decisions
about numbers of layers. Second, the simple linear trans-
formation in the output layer can be optimized fully using
traditional linear modelling techniques, which are fast
and do not suffer from problems such as local minima
which plague MLP training techniques. However the
clumpy approach also implies that RBFs are not inclined
to extrapolate beyond known data: the response drops off
rapidly towards zero if data points far from the training
data are used, therefore they are less reliable for clinical
samples such our one. Detailed review of the models are
reported elsewhere [24,37].
Model development and selection
An "intent-to-treat" analysis was carried out for all
patients who had a baseline assessment and at least 1
assessment after randomization, with the last observation
carried forward on the HAM-D. For the current applica-
tion the inputs to the first layer of the neural network con-
sist of SERTPR and TPH genotypes while the target
outputs consist of response status. The network is then
trained to attempt to predict response from genotypes.
Each node of the input layer of the network is set to a
value representing the genotype of each polymorphism.
For each polymorphism and for each subject this value is
set to genotypes aa, ab or bb. If a marker genotype is miss-
ing then the input is assigned a value equal to the average
of the values for all subjects in the dataset, however no
missing data were present in our sample. The target out-
put for the network is set to 1 or 2 depending on whether
the subject is responding or not.
The best network was selected on the basis of its discrimi-
nating error and performance, positive and negative pre-
dictive values were also reported for each model. This last
was expressed as area under the Receiving Operator Char-
acteristic (ROC) Curve. The area under a ROC curve
ranges from zero to one, with values close to unity indicat-
ing better predictive power; an area of 0.5 indicates that
the model is not predicting better than a random choice.
However, one major problem of NN analyses is to estab-
lish if the prediction from genotypes is greater than would
be expected by chance. If the whole sample is used for
training, the network will to some extent "learn to recog-
nise" particular features of each member of the dataset
and can use these to predict response in a way which may
not reflect any general association between marker geno-
types and disease. Generally, this problem is faced by a set
of strategies: dividing the dataset (50:50, 80:20...), Jack-
knife, bootstrapping, cross-validation and so on. However
those methods present some disadvantages, in particular
if only a part of the data is used to train the network this
leads to a loss of power given that subjects in the validat-
ing part have different patterns of association between
genotypes and drug response.
In order to remedy these problems, in the case of MLP, it
has been suggested to perform both training and testing
on the entire dataset. The statistical significance of any
observed association between outputs and affection status
can be estimated using a permutation test [25].
Once the network was defined, a statistic, denoted T, is
calculated to compare the outputs for responders and non
responders in the same way as an unpaired t statistic,
although the statistic is not expected to follow a t distribu-
tion under the null hypothesis. Instead, in order to esti-
mate statistical significance a permutation procedure is
performed. A large number of replicate data sets are gen-
erated from the original data and the obtained network
model by randomly permuting genotypes with respect to
affection status. For each of these replicate data sets we can
then train and test the data set as before, each time calcu-
lating T. Since each permuted data set will have only ran-
dom association between genotype and affection status
we obtain N values of T which provide a distribution of T
under the null hypothesis. We count the number of times
any of these values exceeds the value of T we obtained for
the real dataset and denote this number R. Then (R + 1)/
(N + 1) provides an unbiased estimate of the statistical sig-
nificance of the association between genotype and affec-
tion status in the real dataset.
In order to estimate a p-value of alpha, one should carry
out approximately 10/alpha replicates. Typically, in order
to detect association at a significance of 0.01 one wouldBMC Medical Genetics 2004, 5:27 http://www.biomedcentral.com/1471-2350/5/27
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perform 1000 replicates (including the real dataset and
999 permuted datasets). In the case of the present paper
we performed 10000 replicates.
Multiple regression and discriminant function analyses
were performed to compare the results obtained with the
NN strategy with traditional techniques. Responder status
was the dependent variable with SERTPR and TPH as
independent variables. Genotypes were scored in the fol-
lowing way according to the hypothesis of codominance
(SERPR*l/l = 1, SERPR*l/s = 2, SERPR*s/s = 2, TPH*C/C
= 1, TPH*C/A = 2, TPH*A/A = 2).
Calculations for the NN selection were performed using
STATSOFT (Kernel release 5.5 A). Evaluation was per-
formed using the NNPERM package [31].
Results
MLP showed the best performance and was therefore
selected over the other networks (see table 1). The MLP
selected over the other models on the basis of error and
performance was composed by 1 hidden layer with 7
nodes (Figure 1) after testing about 150 different MLP
models. The network showed a very good basic perform-
ance (Error 0.430, Performance 0.685).
After, we trained the network with the back propagation
algorithm. Initially we used a learning rate of 0.1
(momentum 0.3, noise set to 0), after 5000 epochs we
reduced it to 0.01 but after 5000 further epochs we
observed no improvement and therefore we finished the
selection process and retained the network. Both poly-
morphisms contributed substantially to the model
(SERTPR error= 0.532, ratio = 1.21; TPH error= 0.450,
ratio = 1.02). This was expected since both markers were
individually associated with response. In detail single
marker significance, calculated as simple allelic chi-
square, was p = 0.00058 for SERTPR and p = 0.025 for
TPH. The classification of subjects in responders and non
responders was 77.5 % for responders and 51.2% for non
responders. Classification may vary depending from the
selected threshold, therefore the area under the ROC curve
is a better indicator of performance, in this case the area
was 0.731. We also evaluated the predictive power of the
network with the SERTPR polymorphism only, in this case
the area under the ROC curve was 0.698. We may there-
fore observe that the add of TPH polymorphism increases
the predictive power of the system.
In order to evaluate the significance of the network we
applied a permutation test with 10000 replicates. The t
statistic for the network was 4.35, it was achieved in 81
out of 10000 simulations yielding a network p-value =
(81+1)/(10000+1) = 0.0082.
Finally, we performed a comparison with traditional tech-
niques. A multiple regression analysis showed a signifi-
cant correlation (p = 0.0004) with a variance explained of
12.5%. The discriminant function analysis correctly classi-
fied 34.1 % of responders and 68.1 % of non responders
(F = 8.16 p = 0.0005).
Following, we tested the possible impact of clinical varia-
bles on response. We included in the model the following
variables: Age, age at onset, sex, education, diagnosis,
presence of delusional features, recurrence index (defined
as number of episodes per year), pindolol augmentation
and baseline HAM-D. With those variables no satisfactory
network was identified. They were therefore not
Table 1: Comparison of NN models. PPV = Predictive Positive Value, NPV = Predictive Negative Value, ROC = area under the ROC 
curve.
Network type Error Performance sensitivity specificity PPV NPV ROC Youden's J
Linear 0.447 0.636 67.12 56.34 75.97 45.46 0.687 0.23
RBF 0.449 0.691 85.61 35.21 73.10 54.35 0.664 0.21
MLP (1 – 7) 0.439 0.682 77.50 51.20 76.35 52.17 0.731 0.28
MLP composed by 1 hidden layer with 7 nodes used for the  analysis Figure 1
MLP composed by 1 hidden layer with 7 nodes used for the 
analysis.BMC Medical Genetics 2004, 5:27 http://www.biomedcentral.com/1471-2350/5/27
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considered as possible confounding factors in the genetic
analysis.
Discussion
This paper reports the first attempt to use NN in pharma-
cogenetic analyses. We applied this technique to short
term antidepressant response in mood disorders. Our
analyses suggest that MLP network is the most appropriate
for this kind of data, in according with previous observa-
tions [25]. The growing number of polymorphisms
(about 3.000.000) and the growth of simultaneous tech-
niques such as gene arrays ask for appropriate techniques
of analysis. Traditional ones have strong limitations not
allowing for non linear interactions and the risk of over-
fitting in the case of multiple polymorphisms analysed in
necessary limited sample sizes. We observed that a rela-
tively simple MLP NN is able to predict response in a way
comparable to traditional techniques. The lack of non lin-
ear interactions in the simple model we analysed [32]
explains why did not observe a marked superiority of NN
over traditional analyses. However the most promising
result of the strategy we tested in the present paper is the
possibility to add a large number of polymorphism to the
network and to evaluate the improvement in the predic-
tion, showed by the area under the ROC curve. Moreover
the significance of the network can be evaluated with the
permutation test [25,31]. Moreover the MLP model we
used is quite parsimonious in terms of parameters used (2
input variables, 1 output variable and 1 hidden layer with
7 nodes).
Further developments of this strategy are the inclusion of
more detailed information on the phenotypic side. The
classification results we obtained are not sufficient in clin-
ical terms were in particular much higher specificities are
needed in order to recognize in advance non responders.
To reach this target we should consider that we previously
observed that some polymorphism influence only part of
the whole depressive symptomatology [38]. Further clini-
cal variables should also be considered as reported to
influence the short term antidepressant outcome [39],
even if previous NN studies failed to identify clinical pre-
dictors of antidepressant response [40]. Our analyses are
in line with this view, in fact the clinical variables we ana-
lysed were not significantly associated with outcome.
The relatively small sample we used does not guarantee
against a possible overfitting phenomenon, therefore
enlargement of the sample is a priority. Moreover we used
the same sample for testing and validating our result, this
is not a standard technique [41], this problem is usually
faced by a set of strategies such as dividing the dataset,
Jackknife, bootstrapping, cross-validation and so on.
However those methods present some disadvantages, in
particular if only a part of the data is used to train the net-
work this leads to a loss of power in the case that subjects
in the validating part have different patterns of association
between genotypes and drug response. Therefore in the
present paper we performed both training and testing on
the entire dataset with the use of a permutation test to val-
idate the results [25]. Another limitation of the present
paper is that we compared NN with multiple regression
only, other techniques could be tested as well such as set
association [30], multifactor dimensionality reduction
[42], and logic regression [43].
Differences in allele frequency for different populations
have been reported [44]. However our sample was com-
posed of subjects mainly collected in the North of Italy
with Italian antecedents for at least two generations,
though genetic heterogeneity have been evidenced for
some isolate populations (such as Sardinia, not included
in our sample) Italy is characterized by a substantial
genetic homogeneity [45]. Another caveat is linked to the
characteristics of our sample. In fact the Center for Mood
Disorders of San Raffaele Hospital is a tertiary structure,
therefore we cannot exclude a potential selection bias
associated with illness severity and possible extension to
outpatients or drug abusers are not warranted [46].
Conclusions
Overall, our findings suggest that neural networks may be
a valid technique for the analysis of gene polymorphisms
in pharmacogenetic studies. The complex interactions
modelled through NN may be eventually applied at the
clinical level for the individualized therapy [47].
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